slides · global inventory
Illustrate Case
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,314
Current window 5,311-5,340
Pages 311
Rows per page 30
Slide function
5,311-5,340 of 9,314
31
The slide uses direct quotes from a Facebook discussion group to highlight the patient/caregiver pain point of symptom detection.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
80
The slide highlights the risk of off-label substitution for the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
87
The slide uses direct quotes to validate the activist's thesis regarding the drug's risks and market limitations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
94
This slide presents qualitative feedback from a medical expert, highlighting significant barriers to adoption for the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
95
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
102
The slide uses direct quotes to support the thesis that generic substitution is likely and that GLP-1s are effective.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
136
The slide uses a 'two-hit' metaphor to describe the synergistic risk of the two medications.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
161
The slide uses anecdotal evidence from Facebook groups to highlight negative side effects (hyperphagia, behavioral changes) associated with the drug VYKAT.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
166
The slide uses anecdotal evidence from Facebook discussion groups to highlight potential adverse drug reactions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
169
The slide uses direct quotes from Facebook discussion groups to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
177
The slide uses anecdotal evidence from Facebook groups to highlight patient dissatisfaction and side effects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
215
The slide uses a Q&A format to validate the thesis that MDCalc is a key driver for off-label drug substitution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
241
The slide uses a quote to establish credibility and validate the activist's research findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
254
The slide uses direct quotes to frame the problem of insurance access as a deliberate strategy of 'playing chicken' by insurers.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
263
Includes a screenshot of a blog post and two photos of the doctor interacting with a child.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
272
The slide uses red arrows to connect the two associations to the town hall event flyer.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
353
The slide uses a Q&A format to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
375
The slide uses highlighted text to emphasize key phrases from the expert's transcript.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
382
The slide uses a Q&A transcript format to highlight the physician's frustration and lack of guidance from the manufacturer.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
397
The slide uses direct quotes to build a case against the company's commercial execution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
405
The slide uses direct quotes from an expert consultation to highlight the drug's perceived lack of efficacy and the barrier of administrative burden.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
406
The slide uses a Q&A format to highlight physician reluctance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
407
The slide presents a summary of an expert interview, highlighting the endocrinologist's preference for GLP-1s over Vykat for PWS patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
409
The slide uses direct quotes to build a narrative of expert doubt.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
411
The slide uses a Q&A format to highlight the administrative burden and slow approval process for the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
415
Includes a Q&A transcript snippet highlighting anecdotal evidence.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
05
The quote highlights a conflict between administrative credit holds and urgent clinical needs for heart transplants.TransMedics (TMDX) · Scorpion Capital
Research note Short seller Beat · Testimonials from Industry Experts1 hit
132
The slide uses a 'villain' narrative framing, comparing the medical system to a cartel and highlighting the 'addiction to volume' as a driver for TransMedics service adoption.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
310
The slide uses direct quotes from transplant surgeons and hepatologists to validate the thesis of market disruption.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
314
The slide uses direct quotes from an organ procurement specialist to validate the thesis of market disruption.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit